Hi [[ session.user.profile.firstName ]]

Life Sciences

  • Metrics to meaning: demonstrating the value of medical communications
    Metrics to meaning: demonstrating the value of medical communications
    Scott McGregor, Allergan, Lynda Chang, Complete HealthVizion, David Pearce, Complete HealthVizion, Dominic Tyer, pharmaphorum Recorded: Jan 23 2019 62 mins
    Medical affairs and publications teams are under increasing pressure to demonstrate effectively the success of the medical communications activities they undertake.

    Naturally, there are a huge number of metrics that could be used to measure and demonstrate medical communications value. The challenge is to identify, and track, those metrics that really matter, and ensure this information is interpreted effectively.

    This pharmaphorum webinar, which will be held in partnership with Complete HealthVizion, will look at how to measure medical communications activities, how to continue with what is successful and how to change what isn’t working.

    This means identifying what can be measured, both in terms of reach and engagement as well as behavioural impact, deciding what ‘great’ looks like and how best to define success.

    The expert panel will also look at how behavioural science can provide a framework to develop smarter communications and, ultimately, drive better patient outcomes.

    This Metrics to Meaning webinar will take place on Wednesday, 23rd January, at 15:00 pm GMT (10:00 EST) and will teach you how to measure the effectiveness of different types of medical communications programmes.

    Interacting with the panel will also allow you to learn about a range of practical approaches to implementing metrics, including:

    • Innovative ways to measure medical communications value and success
    • How to help medical affairs and publications teams demonstrate greater value
    • How to optimise tactical outputs year on year
    • The importance of demonstrating and measuring behavioural change

    In doing so they will also discuss the role of behaviour and the implications of this for measuring success.
  • Extractables from Single-Use Bioreactors and Impact on Cell Culture Performance
    Extractables from Single-Use Bioreactors and Impact on Cell Culture Performance
    Yasser Nashed-Samuel, Principal Scientist at Amgen Donald Young, Sr. Product Manager at Thermo Fisher Scientific Recorded: Jan 22 2019 64 mins
    Attribute Sciences, Process Development, Amgen Biopharmaceuticals are drugs manufactured bygrowing genetically engineered cells in bioreactors to produce a therapeutic protein. Plastic single-use bioreactors are of interest to biopharmaceutical drug manufacturers due to their significant environmental and cost benefits and flexibility over stainless steel bioreactors. Effect of plastics on the biomanufacturing process is not yet completely understood. A case study on extractables from single-use bioreactors and impact on cell culture performance will be presented.
  • Researcher Academy: An introduction to e-learning resources for researchers
    Researcher Academy: An introduction to e-learning resources for researchers
    Priyanka Kalra Recorded: Jan 22 2019 33 mins
    Researcher Academy (https://researcheracademy.elsevier.com/) provides free access to countless e-learning resources designed to support researchers on every step of their research journey. Browse our extensive module catalogue to uncover a world of knowledge, and earn certificates and rewards as you progress.
  • How Researchers & Publishers Can Collaborate In The Move Towards Open Science
    How Researchers & Publishers Can Collaborate In The Move Towards Open Science
    Moderated by Stephane Berghmans, Director Academic Relations, Elsevier Recorded: Jan 21 2019 89 mins
    A debate on challenges and opportunities in open access & open data
  • Single Use Manufacturing within the Bristol-Myers Squibb Manufacturing Network
    Single Use Manufacturing within the Bristol-Myers Squibb Manufacturing Network
    Lance Marquardt, Bristol-Myers Squibb & Sara Bell, Merck Recorded: Jan 17 2019 66 mins
    By Lance Marquardt, Associate Director – Upstream Processing for Hopewell Clinical Manufacturing at Bristol-Myers Squibb and Sara Bell, Senior Marketing Manager for Mercks’s single-use product portfolio.
    An overview of the current use of single use manufacturing within the Bristol-Myers Squibb manufacturing networks and planned future state. The challenges in implementing single use manufacturing for commercial production will be discussed. Comparisons will be made to the implementation of past improvements and the plans for future improvements, such as continuous processing.
  • Overcoming Downstream Bottlenecks In The Upscaling Process
    Overcoming Downstream Bottlenecks In The Upscaling Process
    Dr. Dakshesh Mehta, Associate Vice President and Head of Bioprocess Group at Biotech & Genomics division Recorded: Jan 17 2019 35 mins
    In recent years, due to major advances in upstream process, therapeutic proteins can be produced at higher concentrations than ever before. For, these high-titer, high-cell density production, chromatography operations may be as perceived bottlenecks. Column size limitations, low dynamic capacity and buffer volume requirements are generally considered as contributing factors, apart from high resin costs.

    The talk will cover how flexible manufacturing systems could help establish efficient downstream processes to overcome capacity bottleneck. Also how downstream footprint can be reduced whilst speeding up purification process. Is there anyway, one could eliminate chromatography operations with other technologies that may require less space and buffers and also may be more cost effective?
  • Why Security Matters: Global Insights to the 2018 Unisys Security Index Survey
    Why Security Matters: Global Insights to the 2018 Unisys Security Index Survey
    Tom Patterson, Chief Trust Officer, Unisys Recorded: Jan 16 2019 44 mins
    Despite spending billions of dollars every year on security, companies and governments – as well as the products and services they use – often lose sight of their ultimate goal: protecting the user. Please join this webinar to hear Tom Patterson, the Chief Trust Officer for Unisys, share results and realities from the only recurring snapshot of consumer security concerns conducted globally. This year’s global Unisys Security Index survey brings to light key areas of consumer concern that are vital to understand, if society and the security sector are to be successful in achieving their goals.

    Major findings affecting government services, entire business sectors and fast evolving technologies are all illuminated through the lens of the user, as opposed to the more typical providers. Learn what’s most important to the consumer in each region of the world, and across key demographic categories. This clarity of vision, brought by thousands of statistically significant consumers from around the world, is a voice that needs to be heard.

    Tom will use this year’s results, juxtaposed with over a decade of survey history and informed by global events and leaders from both government and industry, to provide a cogent report on the state of global security from the perspective that matters most—the user.
  • Challenges Faced by the End Users During the Qualification of Single Use System
    Challenges Faced by the End Users During the Qualification of Single Use System
    Ben Jeyaretnam, E&L Analytics Lead of Sanofi at Swiftwater and Dr Andreas Nixdorf, Team Manager at SGS Group Recorded: Jan 14 2019 94 mins
    Pharmaceutical industry has been increasingly using single use systems (SUS) for bioprocessing and storage of intermediate and final bulk material in addition to primary packaging. Before a SUS could be used in the manufacturing process, it needs to be qualified for use by a pre-determined process. This presentation will discuss a variety of challenges, both internal and external to the industry that the end use faces during the qualification process. Complexity of SUS, varying quality of vendor data, component change management, changing regulatory expectations, analytical data generation, logistical challenges during E&L study execution, analytical challenges, and the potential impact of unexpected E&L study results will be presented.
  • Reducing Microbiological Risk & Using Quality Tools in the Pharma Industry
    Reducing Microbiological Risk & Using Quality Tools in the Pharma Industry
    Don Singer, GlaxoSmithKline R&D and Jessica Rayser, Product Manager at Charles River Recorded: Jan 9 2019 55 mins
    The pharmaceutical industry paradigm change is occurring and industry has taken an important leap towards formality of quality improvement using quality tools. Recent industry and regulatory support of ‘risk-based’ concepts and principles are leading to a ‘desired state’ of industry development and production of pharmaceuticals that have a higher level of consistency in meeting purity, safety and efficacy.
    Microbiologists’ role as active partners in the pharmaceutical environment is to help transform industry to a routine Quality by Design paradigm. With the help of quality tools and using the concepts and principles of Quality by Design, a better understanding of how and where to implement microbiological control of processes can be developed, and microbiological purity can be built into products for all patient populations.
  • 3Dスフェロイド培養のアプリケーションとミニチュアライズ
    3Dスフェロイド培養のアプリケーションとミニチュアライズ
    コーニングインターナショナル株式会社 ライフサイエンス事業部 江藤 哉子 Recorded: Dec 20 2018 54 mins
    弊社独自の超低接着表面・形状のプレートを用いた三次元がんスフェロイドや、免疫細胞の作用モデルなどのハイスループットスクリーニング、オルガノイド作製の実例を交えて概説いたします。

    今回は、3Dスフェロイドを使用したアプリケーションをご検討中のみなさまに向けて、基礎から実際のアプリケーションまでをお話しいたします。
  • There's No AI Without IA
    There's No AI Without IA
    Dino Eliopulos, Managing Director, EIS & Bryan Kohl, VP, Business Development, EIS Recorded: Dec 13 2018 48 mins
    Artificial Intelligence (AI) has the potential to completely revolutionize the B2B selling function. And depending on who you talk to, AI will either enable massive productivity gains from your employees or replace them entirely.

    Hype aside, AI is coming, and B2B companies need to understand how to harness it. And despite the promise of ‘plug and play‘ technology, real AI requires varying degrees of knowledge engineering, product and content architecture, and high-quality data sources to be effective.

    In this session, EIS's Bryan Kohl, VP, Business Development and Dino Eliopulos, Managing Director demystify AI for your B2B organization.

    You will learn:

    --How you can leverage best practices to re-think processes for the product content lifecycle, from initial onboarding to post-production syndication
    --The infrastructure you’ll need to consider when planning for your AI initiative
    --How AI enables new product associations and personalized experiences to drive deeper engagement with your customers
  • 6-AM and BUP:  New Useful Assays in the Opiate Crisis
    6-AM and BUP: New Useful Assays in the Opiate Crisis
    Dr. Mary Mayo Recorded: Dec 12 2018 44 mins
    The opiate crisis has reached epidemic proportions, evidenced by more than 17,000 deaths a year and $504 billion in economic costs in the U.S. alone¹. Healthcare providers and laboratories need highly specific tests that accurately detect drugs of abuse in patient-care, employment, athletic and prescription drug monitoring settings.

    In this webinar, Dr. Mary Mayo discusses two highly sensitive assays—the Syva® EMIT® II Plus 6-Acetylmorphine (6-AM) and Buprenorphine (BUP)—that expand available options for drugs-of-abuse testing.

    After attending this webinar, you will be able to describe the:
    • Differences in opioid drugs
    • Magnitude of the opioid epidemic
    • Reasons to use specific drug tests related to opioids
    • Performance characteristics of the Syva EMIT II Plus 6-AM and BUP assays

    P.A.C.E. credit is available for your participation.*

    Presenter: Mary Mayo, Ph.D.

    Dr. Mary Mayo is a medical affairs manager with Beckman Coulter Diagnostics, with more than 25 years’ experience in the clinical laboratory. This includes twelve years as a laboratory director, nine years as director of clinical chemistry at a tertiary-care academic hospital and three years as the laboratory director of a commercial laboratory.

    References:

    ¹ CDC. “Opioid Overdoses Treated in Emergency Departments.” https://www.cdc.gov/vitalsigns/opioid-overdoses/. Accessed 6 Mar 2018.

    *Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.
  • The devil’s in the e-detail: what HCPs really want from you
    The devil’s in the e-detail: what HCPs really want from you
    Heiko Schmidt, Integrated Multichannel Marketing and Sales, Bayer, Sari Ruth Carter, Head of Marketing, Anthill Agency Recorded: Dec 6 2018 68 mins
    Overview:
    Communication; we all do it, it is a critical part of effective business practice and in this pharma is no exception.

    It is no secret that for pharma companies, face time with healthcare professionals (HCPs) has reduced drastically over the last 10 years while the cost of in person engagements has increased significantly.

    Like any customer their expectations for the content they receive have changed, with a focus on useful, succinct and easy to consume materials rather than the sales materials of old.

    So what is it that HCPs want and through this lens, what is it that pharma should be doing?

    The evidence points towards creating meaningful two-way conversations through multiple channels, connecting otherwise siloed touchpoints with and for HCPs in the process.

    For the past 40 years detailing has been the backbone of pharma/HCP communication – but what about e-Detailing? Is it just detailing on an ipad or is it supposed to be something more? How does this fit and what is possible, and more importantly desirable?

    To analyse the current situation and present practical insights, pharmaphorum presents a new free to attend digital debate. Working with our partner Anthill agency we have put together a panel of leading experts from Bayer and Anthill.

    This debate will cover:

    •What is the current landscape for optimal HCP communication?
    •What is the future in terms of HCP channel preference?
    •New technologies in pharma marketing that help you to better engage with HCPs and extend HCP reach – AI, chatbots, self-detailing
    •How to reach more HCPs, when, where and how they want
    •How to overcome low content usage by HCPs
    •The most common challenges for traditional eDetailing effectiveness
    •How to achieve better communication without having to reinvent the wheel
    •How to activate your existing content and reach all customers willing to engage with your brand, regardless of their preference.
  • Next Generation IHC
    Next Generation IHC
    Jeff Gordon Recorded: Dec 5 2018 57 mins
    Immunohistochemistry has now been a staple in diagnostic pathology for decades. This is partially due to pathologist utilization of antibodies in the realm of specialty panels. As the science evolves, the panels evolve, creating demand for the next generation of antibodies to improve diagnostic capabilities. This talk will give an overview of some of these novel diagnostic markers and how they fit into the specialty panels with the traditional antibodies to provide the best diagnostic capabilities to the pathologist, therefore giving the patient the best care available.
  • New Preparation Approach for Improved Pesticide Analysis of Challenging Samples
    New Preparation Approach for Improved Pesticide Analysis of Challenging Samples
    Dr. Frank Michel, Analytical & Chromatography Scientific Advisor, Merck KGaA, Darmstadt, Germany Recorded: Dec 4 2018 58 mins
    For Pesticide Analysis in food and feed QuEChERS is an established Sample Preparation technique. Nonetheless there are some challenging sample matrices that require variations of the classical QuEChERS methodology. These are fat-rich matrices, intensively coloured matrices and dry, complex matrices such as teas, spices or herbs.

    As even the variations in the official methods AOAC 2007.01 and EN 15662:2008 cannot fully remove all matrix interferences, this talk will introduce new sample preparation approaches leading to improved clean-up and recovery of pesticides in these challenging matrices.
  • Machine Learning, Personalized Medicine, and the Future of Drug Discovery
    Machine Learning, Personalized Medicine, and the Future of Drug Discovery
    Gabe Musso, CSO, BioSymetrics Recorded: Dec 3 2018 54 mins
    Despite tremendous achievements in the fields of Artificial Intelligence (AI) and Machine Learning (ML), there remain several areas in healthcare and drug discovery where AI/ML has seen limited success. This includes, notably, improving the high attrition rates associated with discovery of new drugs. As genomic data becomes more widely available and clinical data continue to become digitized, there is an opportunity to use this data to understand and predict drug activity at a more personalized level than ever before. So what limits the application of AI/ML in the precision medicine & drug discovery space? Here we discuss the practical advantages and limitations of AI/ML as it relates to precision medicine and drug discovery, focusing on challenges that need to be addressed before the promise of AI-based approaches can be realized.
  • Literature searching in Health Economics
    Literature searching in Health Economics
    Julie Glanville, Associate Director at York Health Economics Consortium Recorded: Dec 3 2018 51 mins
    Please note: change of date!

    In this webinar, Julie Glanville , Associate Director at York Health Economics Consortium, will discuss literature searching in Health Economics.

    Health economics evidence is a key element in much health services research and particularly in health technology assessments. Health economic models are increasingly used to assist with health care decision making. Identifying economic evidence to inform such research can involve searches in a range of databases and using a variety of strategies.

    This webinar will summarize the key resources which can be searched to identify health economics information including economic evaluations and economic models. We will also explore how to design search strategies to find economic evaluations including economic models. With the closure of key economic evaluation databases (NHS EED and HEED) we will be focusing on how to identify economic evaluations from major bibliographic databases.

    Julie Glanville is Associate Director at York Health Economics Consortium, part of the University of York. Here, she manages systematic review and literature review projects. She also organizes the YHEC training programme.

    YHEC provides a range of research services including literature searches and evidence identification to inform research projects in healthcare topics but also in other fields such as food safety and feed safety, social care, housing, criminal justice and education. YHEC contributes to the evidence base for information retrieval with a special focus on identifying economic evidence and search filters (strategies) for a range of research methods.

    YHEC carries out systematic and non-systematic reviews for a range of clients to identify the effects of drugs, devices and other interventions. The training program also partners with Quantics Consulting to provide indirect treatment comparisons (ITCs) and mixed treatment comparisons (MTCs).
  • Industry Perceptions and Expectations - The Role of ICER as an Independent HTA
    Industry Perceptions and Expectations - The Role of ICER as an Independent HTA
    Mike Pace, Sr. Principal, Global Pricing & Market Access; Nathan White, Senior Vice President, Integrated Access & Outcomes Recorded: Nov 28 2018 63 mins
    This webinar explores:

    - The evolution of health technology assessment in the US and possibilities for the future
    - Opinions of manufacturers and US payer stakeholders on the role of - - ICER in the US healthcare system, as learned through a primary research study of more than 50 participants
    ICER methodologies and approaches to evaluation of clinical and health economic evidence
    - Ways manufacturers can begin to more proactively prepare for an ICER assessment
  • Can simulated datasets unlock the potential of patient data?
    Can simulated datasets unlock the potential of patient data?
    Jem Rashbass, Health Data Insight, Chris Carrigan, use MY data, Adam Reich, IQVIA, Dominic Tyer, pharmaphorum Recorded: Nov 27 2018 68 mins
    Patient level data offers the promise of insights which can craft new and better pathways, enable development of innovative therapies and treatments, and of course identify and prevent diseases much earlier in their lifecycle.

    One area of particular interest is cancer. However, in trying to realise the potential, the health sector is faced with the conundrum of protecting patients’ identities, while at the same time allowing doctors access to their data and enabling industry to benefit from vital insights into the disease.

    This presents a paradox, as the UK has some of the best healthcare data in the world, however, accessing the data can be challenging and time consuming due to patient confidentiality checks.

    So, what is the solution?

    IQVIA brings a unique perspective to this event, having partnered with Health Data Insight to develop an innovative solution to this seemingly intractable problem: Simulacrum, a database comprised of only artificial data that is modelled on real patient data collected by the National Cancer Registration and Analysis Service (NCRAS) in England.

    Simulacrum has already produced identical results to the real data when predicting incidence of tumours in the population, whilst simultaneously removing any risk of breaching patient confidentiality.

    In this webinar, IQVIA and pharmaphorum will also provide advice to industry, patient advocacy groups and healthcare professionals on how to leverage Simulacrum, and utilise this simulated dataset to facilitate access to England’s world-leading healthcare data, while complying with regulations designed to protect and maintain individual confidentiality.
  • How to accelerate FTO searches on sequences by 70%
    How to accelerate FTO searches on sequences by 70%
    Jessie Parker @ PatSnap Recorded: Nov 21 2018 35 mins
    Scientists in the biotech and pharma industries spend a large amount of time and resources on researching sequences. However, often as researches progress to the later stages of R&D, they become blocked by competitors and products that are already on the market.

    Using a sequence searching tool which links to patent data can help you identify obstacles and freedom to operate much earlier on. Having access to a full data set sooner, can help you save time, money and enhance your R&D.

    Join this webinar to find out how you can accelerate FTO searches on your sequences.
  • How to drive digital agility & efficiency in the Pharma & Life Sciences industry
    How to drive digital agility & efficiency in the Pharma & Life Sciences industry
    Sean Donnelly (Econsultancy), Toby Donnison (Pharma Lead - Adobe), and Rupert Wills (Solutions Consultant - Adobe) Recorded: Nov 21 2018 55 mins
    The 2018 Digital Trends report released by Adobe & Econsultancy found that only 5% of healthcare and pharma organizations reported being digital-first. Yet in today’s digital world, there has never been a better time for the Pharma industry to innovate and improve health outcomes whilst driving business performance. Technology has sparked a revolution across all functions, from research and development to sales and operations. However, meeting these demands is not without its challenges. The unique nature of the pharma and life sciences industry means that it faces issues that other businesses do not have to grapple with. There are complex supplier networks, growing regulatory requirements and increasing pressure to reduce costs – so what can digital leaders do to effect change quickly?

    Join Econsultancy & Adobe in this webinar to learn:
    • The reality of the digital first challenge and the trends causing complexity.
    • How technology is shaping the future and the opportunities for digital agility & efficiency.
    • How Merck transformed time consuming business processes though digital workflows – accelerating business, and improving the employee & customer experience.
    • How electronic signatures can digitally transform your documents and workflows, accelerating an organisations digital transformation journey.
    • How to ensure you stay compliant with regulations including a live demonstration the BioPharma module (covering Title 21 CFR Part 11)
  • 多段型セルカルチャーおよびマイクロキャリアによる細胞培養技術セミナー
    多段型セルカルチャーおよびマイクロキャリアによる細胞培養技術セミナー
    コーニングインターナショナル株式会社  ライサイエンス事業部 石渡 孝至 Recorded: Nov 21 2018 61 mins
    バイオロジクスの治験薬製造における効果的な細胞培養と分離工程の簡素化を実現させる幹細胞・癌細胞の基礎的培養技術を概説いたします。
    今回は、大量培養に向けたシングルユース技術導入のポイントを概説します。

    <セミナーのポイント>
    実際に静置型/撹拌型のシングルユース培養容器を使用した時のヒト間葉系幹細胞(hMSC)及びヒト胎児腎細胞(HEK293T)の培養データを例示します。
  • Evolve Manufacturing Processes by Implementing Disruptive Technologies
    Evolve Manufacturing Processes by Implementing Disruptive Technologies
    Yuyi Shen, Associate Director at Bolt Bio, John Cyganowski, Director of Manufacturing Sciences for MilliporeSigma Recorded: Nov 19 2018 77 mins
    The desire for innovative technology that can eventually cause disruptive changes remains high in the biotech pharmaceutical industry. The road between pursuing and developing that technology to genuine implementing is not a smooth ride. In this webinar, the presenter identifies key challenges of implementing innovative technologies and the major drive for implementing innovative technologies and process upgrades. The presenter will share some case studies of implementing successful innovation tools and provide comparative economic analysis based on the understanding the true value of innovation driven process design. The webinar also provide the insight of the balance needs for quality, cost and speed.
  • More Success in LC-MS: Tips and Tricks for Sample & Mobile Phase Preparation
    More Success in LC-MS: Tips and Tricks for Sample & Mobile Phase Preparation
    Vivek Joshi, PhD Recorded: Nov 15 2018 46 mins
    LC-MS is one of the most commonly used analytical techniques in various sectors for quantitation and identification of unknown from variety of complex samples. Use of LC-MS has expanded over the years as it offers both selectivity and specificity in analysis. With advances in both chromatography and mass spectrometry, sensitivity and accuracy of this technique has further increased, allowing for detection and identification of low-level analytes in complex sample matrices.

    The LC-MS workflow has three main components, which determine successful analyses: sample preparation, choice of mobile phase components and column selection. Not paying enough attention to one of these components can complicate data analysis, quantitation and identification.

    In this seminar, you will learn critical factors to consider when selecting the sample preparation methods, mobile phase components and HPLC columns.
  • Mixed mode Chromatography in Purifying biologics - Overview
    Mixed mode Chromatography in Purifying biologics - Overview
    Vivek Halan Zumutor Biologics Pvt Ltd, Bangalore, India Recorded: Nov 15 2018 42 mins
    This Webinar will discuss MMC in purifying biologics which includes monoclonal antibodies (mAbs), Bispecific antibodies (BsAbs), antibody fragments (Scfv,Fab) and other recombinant proåteins. My discussion is intended for audience from biopharmaceutical industry as well as active collaborators from academic institutes.
  • Raw Material Lot Variability Challenges During Manufacturing of Biosimilars mab
    Raw Material Lot Variability Challenges During Manufacturing of Biosimilars mab
    Sekhar Reddy, DSP Lead for Biosimilars at Biocon MSAT Jan 25 2019 10:00 am UTC 75 mins
    Downstream processing of Biosimilar Monoclonal Antibody utilises variety of raw materials that a critical for achieving the desired product quality. In this webinar, we would like to discuss the data from three cases of lot to lot variability namely Depth filtration, Chromatographic resin and buffer component used in downstream chromatography unit operations. Changes in lots of depth filter resulted in significant clogging and differences in Host cell impurity clearance. Similarly, changes in resin lots resulted in increased back pressure during processing and variability in buffer raw material lots resulted in undesirable colouring of resin upon contact. In each case, we will present the root cause investigation, impact on product quality profile and associated CAPAs to control the effects of variability to ensure manufacturing continuity.
  • Cancer, genomics and personalised medicine: Modelling the future of oncology
    Cancer, genomics and personalised medicine: Modelling the future of oncology
    Danyi Wen, Shanghai LIDE Biotech, Stefan Jellbauer, Mitra Biotech, Lakshmi Santhosh Maithel, Repositi Jan 29 2019 4:00 pm UTC 75 mins
    The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in 2 people in the UK and 1 in 2 men/1 in 3 women in the US will experience it at some stage in their lives. And yet the picture for patients is an improving one.

    The move towards immunotherapies heralds much promise and this is potentially just the beginning. As cancer is understood increasingly not by type, or even tumour type but specific mutation the era of personalised oncological therapies is visible.
    To delve further into this pharmaphorum is pleased to present an exclusive online discussion.

    Bringing together experts at the cutting edge of this field it aims to interrogate where we are in terms of this shift towards personalised oncology, what this means in terms of the development pathway and looks at the approaches which could (and will) fully evolve the way that cancer treatments are developed in terms of efficacy, approach and outcome.

    this free to attend event will cover a number of topics critical to the future of oncology including:
    •The changing face of cancer: how do we define it now?
    •Personalised medicine in practice – where are we now in cancer?
    •What are the implications from these changes for clinical trials?
    •How the shift towards cancer as a phenotype/genotype is being applied in clinical trials and how they are run
    •What are co-clinical trials and why could they hold the key to answering unmet need in cancer treatment and beyond into broader drug development?
    •Modelling for the future of cancer – can this be done for personalised therapies?
  • The Real State of Digital Business for 2019
    The Real State of Digital Business for 2019
    Seth Earley, CEO, Earley Information Science & Jennifer St. Hill, COO, Earley Information Science Jan 30 2019 6:00 pm UTC 60 mins
    How far along are we when it comes to digital transformation? EIS set out to discover the answer by launching an industry-wide ‘State of Digital Business’ Survey which asked respondents to share their data readiness, planned digital projects, future goals, and more.

    This month, we’re ready to share these results with you. Join Seth Earley, Founder and CEO, Earley Information Science, and Jennifer St. Hill, COO, as they present results from our December 2018 ‘State of Digital Transformation Survey.’

    You will learn:

    **The trends your peers are experiencing that are driving digital business initiatives within your organization.
    **The challenges your peers are facing when implementing a digital business strategy, as well as the tactics they’re using to overcome those challenges.
    **Common (and not so common) digital business initiatives that are underway within your peer companies.

    We hope you'll join us on January 30th at 1:00PM ET to find out "The Real State of Digital Business for 2019."
  • Using In-Vitro Dissolution to Support Post Approval Changes Global Regulatory Ex
    Using In-Vitro Dissolution to Support Post Approval Changes Global Regulatory Ex
    Dr Xin Bu, Principal Scientist, Bristol-Myers Squibb Feb 5 2019 3:00 pm UTC 75 mins
    Dissolution is one of the critical quality attributes for solid oral dosage forms, typically tablets and capsules. In addition as a quality control (QC) test to release commercial products, dissolution is often used as a comparative test to 1) apply biowaiver for lower strength(s) when multiple strengths of one product with the same or similar formulation are marketed, or 2) support post approval changes. In these cases, in-vitro dissolution test is used in place of in-vivo bioequivalence study to establish equivalency between products of different strengths or pre- and post-change. Guidances provided by major regulatory agencies, the United States Food & Drug Administration (US FDA) and European Medicines Evaluation Agency (EU EMEA) are often followed by many countries around the world. However some countries/ regions, such as Australia, Japan, China, Taiwan and Korea have their own country specific guidances. The dissolution requirements by the FDA and EMEA are generally similar, and depend on the type and level of changes as outlined in the relevant guidances. The requirements from other mentioned countries are often significantly different from that of US and EU, and different from each other. For products marketed globally, it’s prudent to understand the differences amongst the different country requirements when applying post approval changes using dissolution to demonstrate equivalency. Several sets of comparative dissolution studies may have to be conducted in order to satisfy all regulatory agencies. This presentation compares differences in dissolution testing requirements among the listed countries and provide examples to illustrate how for conduct studies to comply with the relevant guidance(s).
  • Just What the Dr Ordered for UK Life Sciences? The 2nd Life Sciences Sector Deal
    Just What the Dr Ordered for UK Life Sciences? The 2nd Life Sciences Sector Deal
    Erik Nordkamp, President, ABPI, Managing Director, Pfizer, Angela McFarlane, Market Development Director, IQVIA Feb 7 2019 12:45 pm UTC 75 mins
    Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS.

    With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.

    This pharmaphorum webinar, held in partnership with IQVIA, will analyse the current and future landscape for UK life sciences as well as what steps have been taken so far to boost the sector.

    Panellists from across the industry will look at the challenges presented by the current situation with Brexit and how the 10-Year Plan and the Sector Deal 2 (or 2018) play into this. They will discuss the positive steps taken by the government to prepare NHS innovation for a radically different future and make sure the UK remains an attractive location for ongoing inward investment from global pharma.

    Topics to be covered include:

    •Highlights of the 10-Year Plan and the second Sector Deal
    •Progress with the current Life Sciences Industrial Strategy, the Sector Deal and plans for 2019
    •The NHS innovation uptake agenda
    •Maintaining UK attractiveness for inward global pharma and biotech investment
  • Host Cell Protein Characterisation and Mass Spectrometry Strategies
    Host Cell Protein Characterisation and Mass Spectrometry Strategies
    Xuezhi Bi, Group Leader (Proteomics) /Senior Scientist, Bioprocessing Technology Institute, A*STAR  Feb 19 2019 8:00 am UTC 75 mins
    Adding Mass Spectrometry as part of the host cell protein workflow
    Analytical Strategies in HCP identification and purification process
    Developing Quantitative MS/MS method to determine HCP Levels
  • Quality-By-Design in Spray Drying Processes - Transfer Lab to Production
    Quality-By-Design in Spray Drying Processes - Transfer Lab to Production
    Sune Klint Andersen, Janssen Pharmaceutica & João Vicente Senior Scientist - Particle Engineering Team Leader at Hovione Feb 19 2019 3:00 pm UTC 75 mins
    Spray drying is a continuous and scalable manufacturing process commonly used in the pharmaceutical industry. Due to its scalable and continuous nature it is possible to apply Quality-by-Design (QbD) and Process Analytical Technologies (PAT) early on in the development of a spray drying process.
    Knowledge gained from QbD e.g. Design-of-Experiments (DoE) and PAT increases process understanding and the knowledge can be readily applied when scaling up the process and in production scale application of PAT i.e. especially with respect to the control strategy.
    The Webinar will discuss the application of QbD early in the development and how the obtained knowledge can be used to optimize transfer of the spray drying process to production scale including PAT strategy.
  • PDA Technical Report on Low Endotoxin Recovery: Implications to the Industry
    PDA Technical Report on Low Endotoxin Recovery: Implications to the Industry
    Dr Friedrich von Wintzingerode, Senior Manager, Global Analytical Science & Technology (gASAT) Microbiology, Global QC bei Ro Feb 21 2019 9:00 am UTC 75 mins
    Since first reported by Chen and Vinther in 2013, the phenomenon known as low endotoxin recovery (LER) has been broadly observed in certain matrices commonly used for biologic formulations and certain therapeutic proteins. LER is defined as the inability to recover >50% activity over time when endotoxin is added to an undiluted product. LER is a temperature-and time dependent process, which usually does not occur immediately but after several hours to several days. Compendial LAL method qualification (Bacterial Endotoxin Test = BET per USP /EP 2.6.14/JP 4.01) does not include defined hold time conditions, which may explain why LER has not been detected by following compendial BET guidance. Because of the potential impact to patient safety and complex nature of the LER issue, the Parenteral Drug Association (PDA) published a Technical Report (TR) on LER. This TR was authored by subject matter experts from academia, U.S. FDA, biopharmaceutical companies, and reagent suppliers/testing contractors. The PDA Technical Report on Low Endotoxin Recovery provides a science-based and data-driven strategy in dealing with the LER phenomenon. The author of this article, who acted as co-lead of the TR authoring team, provides first hand information that allows companies to develop product specific solutions to the LER problem.
  • How to drive digital agility & efficiency in the Pharma & Life Sciences industry
    How to drive digital agility & efficiency in the Pharma & Life Sciences industry
    Sean Donnelly (Econsultancy), Toby Donnison (Pharma Lead - Adobe), and Rupert Wills (Solutions Consultant - Adobe) Feb 21 2019 2:00 pm UTC 54 mins
    The 2018 Digital Trends report released by Adobe & Econsultancy found that only 5% of healthcare and pharma organizations reported being digital-first. Yet in today’s digital world, there has never been a better time for the Pharma industry to innovate and improve health outcomes whilst driving business performance. Technology has sparked a revolution across all functions, from research and development to sales and operations. However, meeting these demands is not without its challenges. The unique nature of the pharma and life sciences industry means that it faces issues that other businesses do not have to grapple with. There are complex supplier networks, growing regulatory requirements and increasing pressure to reduce costs – so what can digital leaders do to effect change quickly?

    Join Econsultancy & Adobe in this webinar to learn:
    • The reality of the digital first challenge and the trends causing complexity.
    • How technology is shaping the future and the opportunities for digital agility & efficiency.
    • How Merck transformed time consuming business processes though digital workflows – accelerating business, and improving the employee & customer experience.
    • How electronic signatures can digitally transform your documents and workflows, accelerating an organisations digital transformation journey.
    • How to ensure you stay compliant with regulations including a live demonstration the BioPharma module (covering Title 21 CFR Part 11)
  • Effect of Cell Culture Process Change from Fed-batch to Continuous on...
    Effect of Cell Culture Process Change from Fed-batch to Continuous on...
    Ru Zang, Associate Director at Mersana Therapeutics and John Bonham Carter, Director of Upstream Sales at Repligen Feb 25 2019 4:00 pm UTC 75 mins
    EFFECT OF CELL CULTURE PROCESS CHANGE FROM FED-BATCH TO CONTINUOUS ON PRODUCTIVITY AND PRODUCT QUALITY

    Integrated continuous bioprocessing has attracted a growing interest due to its potential to improve agility and flexibility in the manufacture of therapeutic proteins. To convert an existing fed-batch cell culture process to continuous, or perfusion, the major technical hurdles include maintaining steady state cell culture performance and generating product with comparable product quality attributes. In this presentation, we evaluated three molecules including a fusion protein, an aglycosylated monoclonal antibody (mAb), and a glycosylated mAb. Steady state culture at high cell density was achieved for all three molecules, which allows the delivery of products with consistent product quality and adequate productivity. However, as compared to fed-batch processes, product quality and cell specific productivity differences were observed in perfusion cultures. Further studies indicated that it was feasible to modulate product quality in perfusion process by adding process levers in culture medium. It was also feasible to increase cell specific productivity through medium and process optimization. This presentation provides an insight into the product quality and productivity differences between traditional fed-batch and perfusion cell culture processes and potential approaches to addressing these differences.
  • Continuous Manufacturing: Business Case Drivers and Deployment Strategies
    Continuous Manufacturing: Business Case Drivers and Deployment Strategies
    Lawrence De Belder, Senior Principal Engineer at Johnson and Johnson and Richard Steiner, Business Development Manager at GEA Feb 26 2019 4:00 pm UTC 75 mins
    Continuous manufacturing for Oral Solid Dose drug products has the potential to generate benefits in many different areas of the product life cycle. It will help to improve control and understanding, increase development and transfer speed, assure shorter cycle times, and reduce development, transfer and operational cost.

    If we look at the products which have been approved for commercial production, we see differences in technology, approach, and business case drivers. The main interest is coming from larger pharmaceutical companies, but also generic companies and CMO’s start to invest or have intentions to do so.

    Before implementing a continuous manufacturing process, a number of strategic choices have to be made: start off immediately with new products or learn by converting a legacy batch product into a continuous process without the critical deadline of a launch on your path. A clear development and deployment strategy will help to guide for important choices early on.

    This webinar will give an overview of the different elements that can drive the business case of a continuous manufacturing project, and which strategies could be used to deploy this wonderful technology throughout an organization.
  • Fundamentals of IHC Stain Troubleshooting
    Fundamentals of IHC Stain Troubleshooting
    Ourhay Shamoon Feb 27 2019 4:00 pm UTC 75 mins
    Come one, come all to the troubleshooting gallery as we learn sure-fire techniques to troubleshoot IHC stains. Inappropriate stains impact patient care, slow your lab down, and waste reagents, all of which cost your lab money, time, and peace of mind. This workshop will cover common histology and immunohistochemistry protocols, paying close attention to how each step influences stain quality. We’ll take aim at the root cause for most stain issues and set our sights on the red flags to look for when troubleshooting. We’ve got you covered from specimen collection to cover slipping. Too Light, Too Dark, Background, No Stain and the rest of the outlaws won’t stand a chance. You’ll mosey out of this workshop with a thorough understanding of how histology and immunohistochemistry work to produce a quality stain and the tools you will need to efficiently troubleshoot the most common stain issues. Giddy up and count yourself among the ranks of ‘Sharp Troubleshooter’ for your lab.
  • Real Time Online Chromatography Monitoring of Product Quality Attributes for Bio
    Real Time Online Chromatography Monitoring of Product Quality Attributes for Bio
    Dr. Gang Xue, Scientific Director at Amgen Inc Feb 28 2019 3:00 pm UTC 75 mins
    REAL TIME ONLINE CHROMATOGRAPHY MONITORING OF PRODUCT QUALITY ATTRIBUTES FOR BIOLOGICS CONTINUOUS MANUFACTURING PROCESS

    The ever diversifying therapeutic modalities drive for modular and flexible bio-manufacturing, which transformed biologics process from traditional Fed-batch to Single Use BioReactor (SUB), then to Continuous Manufacturing (CM). Process Analytics evolve as critical enabling element of the CM process. It allows to move the release testing from the end of process to real time in the process, which not only eliminates weeks of material disposition delay, but also provides the process scientists product quality insight during the run to make process decisions. However, due to the structural complexity of the bio-molecules, spectroscopic sensors or probes nowadays lack the sensitivity and specificity to illustrate the product quality attributes (PQA) such as protein post translational modifications (PTM). We report here for the first time, we leverage a multi-functional automation system to directly take samples from the different stage of bio-process, purify, denature, derivatize and digest the samples before injecting onto the UHPLC and UHPLC/MS systems, one for online intact protein analysis, the other for Multiple Attribute Method (MAM) analysis for critical PTM PQAs. Benefiting from the high resolution chromatography and mass spectrometry, automated real time bio-molecule product quality monitoring is achieved for both SUB and CM process.

    Dr. Gang Xue is a Scientific Director at Amgen Inc. located in Cambridge, MA. With B.S. degree in Chemistry and B.E. in Computer Science from Tsinghua University and Ph.D in Analytical Chemistry from the Iowa State University, Gang is currently leading the Process Analytics group within Amgen Process Development organization. One of his group’s focuses is the cross modality PAT strategy for the biologics and synthetic continous manufacturing with the goal of process control and real time release testing
  • Challenges in the Development of Continuous Processes for Vaccines
    Challenges in the Development of Continuous Processes for Vaccines
    Danny Vellom, Senior Director, Global Technology and Innovation at Sanofi Pasteur Biologics, Inc. Mar 4 2019 4:00 pm UTC 75 mins
    The development and application of continuous manufacturing processes for vaccines presents both great opportunity as well as significant challenges, both technical and cultural, for the global industry. The key drivers are manufacturing capacity and flexibility, speed to market, and improved quality through the application of Quality-by-Design and Process Analytical Technology (QbD/PAT). Given the diversity of immunogens (toxoids, conjugate and subunit vaccines, live-attenuated and inactivated viruses, VLPs, etc.), and the variety of unique processes currently utilized to produce either single- or multi-component vaccines, it is unlikely that the transition to continuous processing will happen overnight. Additionally, cultural challenges are faced whenever a new mode of operation appears to some as “too different”, especially in a traditionally conservative sector like the developed-world vaccine industry. That said, market forces, global climate change, and Nature’s propensity to fill unoccupied niches with emerging infectious diseases will undoubtedly induce a first round of pioneers to explore this exciting new design space, ultimately leading to a more nimble industry and more and better opportunities for protection for the global population.
  • Lifecycle management of single use technologies
    Lifecycle management of single use technologies
    Francis Verhoeye, Director Single Use Technologies, GSK Vaccines Mar 5 2019 1:00 pm UTC 75 mins
    Single-use technologies (SUTs) are one of the key drivers in the biopharmaceutical industry today and are changing the way we are operating and qualifying our bioprocesses, offering more flexibility and increasing efficiency. However, the extended use of those technologies in commercial operations requires a robust and specific lifecycle management approach. In this context, we have built an improved technical lifecycle management approach involving close partnership with key suppliers, enhanced standardization, early involvement of global manufacturing functions and full compliance with item creation process in order to ensure business continuity and value creation.
  • Risk Based Approaches To Use Of Closed Systems In Renovations Of Existing Biopha
    Risk Based Approaches To Use Of Closed Systems In Renovations Of Existing Biopha
    Lars Hovmand-Lyster of Novo Nordisk GPO and Ernest Jenness of MilliporeSigma Mar 5 2019 3:00 pm UTC 90 mins
    Risk Based Approaches To Use Of Closed Systems In Renovations Of Existing Biopharma API Facilities

    Companies often experience regulatory challenges during inspection of aging facilities, requiring them to initiate projects to optimize product protection and updating to current standards for classified areas for biopharma manufacturing. For a long time the company response have been to improve the existing classified areas or maybe even upgrading to a higher grade of classification. However, it may be more appropriate, and improve product protection, to instead implement the use of closed system processes and downgrade room classification during these facility renovation projects. If closed systems are fully utilised, then a CNC space can be used. As well as reducing complexity of operations, this will reduce capital and operating costs.
    This presentation elaborates the work of BPOG members to harmonize the use of closed systems and define risk based tools and approaches to evaluate appropriate room classification across the Biopharmaceutical industry.
  • FROM EARLY STAGE TO LATE STAGE DEVELOPMENT: HOW TO CHARACTERIZE A PERFUSION-...
    FROM EARLY STAGE TO LATE STAGE DEVELOPMENT: HOW TO CHARACTERIZE A PERFUSION-...
    Perrine Rouel, Janssen Pharmaceutical Companies of Johnson & Johnson and Tom Jeffery, Sartorius Stedim Biotech Mar 7 2019 3:00 pm UTC 75 mins
    FROM EARLY STAGE TO LATE STAGE DEVELOPMENT: HOW TO CHARACTERIZE A PERFUSION-BASED VACCINE PRODUCTION PROCESS USING QBD?
    The biopharmaceutical industry is known for its long time-to-market and for requiring large resources and time investment for product development. The type of activities required at the start of a biopharmaceutical product development focus mainly on designing a suitable process for manufacturing as rapidly as possible material to be tested in pre-clinical and clinical trials. This is followed, upon success in early clinical trials, by a process optimization phase, which aims at increasing yields while reducing costs-of-good. Moving on towards late stage development, the manufacturing process needs to be characterized, meaning that its robustness to produce the desired product quality when operated within certain process ranges needs to be demonstrated. This phase requires large numbers of development batches using elaborate analytical methods and advanced statistics, in order to fully study the relations between the manufacturing process and product quality.
    Janssen Vaccines has transitioned over the last 3 years from early stage process development to full late stage development programs. In this presentation, we present the implications of such a transition, with the case-study of the QbD-based characterization of a perfusion-based PER.C6® cell culture process for Adenovirus vaccine production at Janssen Vaccines.
  • Achieving Seamless Scale-Up and Technology Transfer – A Case Study in Single-Use
    Achieving Seamless Scale-Up and Technology Transfer – A Case Study in Single-Use
    Ying Wang, Ph.D., Senior Scientist I, Manufacturing Sciences at AbbVie Bioresearch Center Mar 11 2019 3:00 pm UTC 75 mins
    Title: Achieving Seamless Scale-Up and Technology Transfer – A Case Study in Single-Use Bioreactors

    A systematic scale-up strategy is critical in enabling a rapid and robust technical transfer. For a program involving a CHO cell culture process, a combination of mass-transfer (kLa) studies, computational simulation and scale-down model experiments were used within this newly developed work-flow. Utilizing this approach, scale-up was successfully accelerated (
  • Managing Biologics Process Analytical Technology in Pfizer
    Managing Biologics Process Analytical Technology in Pfizer
    Keith Davis, Principle Scientist at Pfizer Mar 12 2019 3:00 pm UTC 75 mins
    Coordinating PAT between development and manufacturing organizations is always challenging. When there are multiple development sites and numerous manufacturing sites, this becomes especially challenging. In order to help manage this in an efficient manner, we have established a PAT SME network with representation from the Manufacturing and the Development organizations. I will briefly introduce how this team facilitates PAT activities and attempts to add value to both organizations.
  • Integrity Assurance for SUS: End-User Perspective
    Integrity Assurance for SUS: End-User Perspective
    Charlotte Masy, Project Manager in global support GSK vaccinés and Donald Young, Sr. Product Manager at Thermo Fisher Scienti Mar 14 2019 9:00 am UTC 75 mins
    Single Use technologies are more and more used close to final product leading to increase concern related to integrity. In this article we would like to share supportive data affecting integrity. Defect mode analysis has allowed us to build a risk assessment and a strategy on integrity. This strategy is very important for critical applications when single use are used after last sterile filtration or in process no sterile filtration is possible.
    Several case studies supporting our approach will be shared showing the importance of addressing integrity in the context of use and taking all technical aspect into consideration. Finally, we will also present data analyzing the effect of such a strategy on lowering defect occurrence .
  • Understanding the Propensity of Sequence Variants During Cell Line & Culture...
    Understanding the Propensity of Sequence Variants During Cell Line & Culture...
    Dr. Lisa Marzilli, Associate Research Fellow and group leader Mass Spectrometry at Pfizer, USA Mar 18 2019 3:00 pm UTC 75 mins
    Sequence variants (SVs) are protein isoforms that contain one or more unintended amino acid substitutions. They can arise at a single amino acid site due to a genetic (RNA/DNA) mutation or at multiple amino acid locations, potentially due to translational errors, also referred to as misincorporations. The ability to detect SVs in protein biotherapeutics is critical due to their potential impact on structural/functional characteristics, safety and efficacy. Trypsin peptide mapping with liquid chromatography-ultrahigh resolution tandem mass spectrometry (LC-MS/MS) provides the ideal workflow for the detection, identification, and relative quantitation of both genetic and translational SVs. LC-MS/MS complements next-generation sequencing (NGS) of product cDNA and amino acid analysis (AAA) of cell culture medium during clone selection and process optimization in providing sensitive, comprehensive screening to strategically prevent/minimize SVs and ensure high product quality.

    The occurrence of genetic SVs was evaluated using Sanger sequencing and LC/MS. In this work, mAbs with known high and low-level genetic SVs were studied at various cell culture conditions including scale, process and cell age. While scale and process had no significant impact on genetic SV levels, low-level SVs were found to decrease with cell age whereas high level SVs remained constant.

    Multiple cell culture process options and the final process conditions are analyzed via LC-MS/MS prior to lock-down of the manufacturing process. Additionally, the cell culture medium (days in culture) for all small scale, pilot and clinical batches are analyzed by AAA to ascertain amino acid nutrient levels, which provides indirect monitoring of possible misincorporation situations. For mAbs with confirmed misincorporations, AAA and LC-MS/MS-peptide mapping results primarily correlated with amino acid nutrient depletion.
  • Transformational Science: Moving from Challenges of High Concentration Protein..
    Transformational Science: Moving from Challenges of High Concentration Protein..
    Sachin Dubey, Ph.D., Head of Formulation and Analytical Development at Glenmark Pharmaceuticals SA Mar 19 2019 3:00 pm UTC 75 mins
    TRANSFORMATIONAL SCIENCE: MOVING FROM CHALLENGES OF HIGH CONCENTRATION PROTEIN FORMULATIONS DEVELOPMENT TO MEET THE NEEDS OF HIGH POTENT BISPECIFICS
    Monoclonal antibodies (mAbs) have significantly contributed in the treatment of oncological and immunological disorders over last two decades. Next advancement in this line is the introduction of bispecific antibodies – molecules which can bind to two different receptors at the same time. Engaging T-cells to target tumor cells and eventually killing tumor cells have been clinically demonstrated by such bispecific antibody. Traditionally one of the key challenge for developing mAbs is to administer high quantities of mAbs, on the other hand bispecific antibodies are extremely specific and more efficient, which makes them highly potent – leading to a reduced dose. This turns the focus from developing high concentration formulations for mAbs to the development of low concentration formulations. Scientific challenges are of very different nature with surface adsorption being the key challenge; during drug product manufacturing as well as during clinical dosing a protein molecules encounters various different surfaces and preventing/controlling adsorption on any of these surfaces is important. Analytical methods are also required to be adapted for reliable low concentration measurement for the drug product as well as the diluted preparation for infusion in clinic.
  • mAb Industry in China: Biosimilars vs. Innovative Biologics
    mAb Industry in China: Biosimilars vs. Innovative Biologics
    Dr. Joe X Zhou is the CEO Walvax Bio Group & Floris D Smet, Director of Field Marketing, Sarotrius China Mar 21 2019 8:00 am UTC 75 mins
    Following patent cliffs for Erbitux, Rituxan, Sandosta_n and several big blockbusters, Herceptin, Avastin are now among the next biosimilar targets. This is creating huge potential for biosimilars, prompting innovators to shift their focus to target more emerging markets which remain untapped for many companies. In this presentation, Joe will be sharing with you his vision of the biosimilars market with a focus on China. He will also discuss key considerations for mAb and biologics therapeutic development, providing a broad overview of challenges and opportunities presenting in the market.
     
    1.        Landscape changes of mAb therapeutics
    2.        New targets and process/manufacturing innovation
    3.        Key consideration of mAb industry in China
    4.        Case study: Development strategies of PD-1 mAb as anti-tumor therapeutics in China for global market
  • Extractables and Leachables have been used interchangeablely for too long. Are w
    Extractables and Leachables have been used interchangeablely for too long. Are w
    Ken Wong, Deputy Director at Sanofi Pasteur and Diego Zurbriggen, Technical Account Manager at West Pharma Mar 25 2019 2:00 pm UTC 75 mins
    Title: Extractables and Leachables have been used interchangeablely for too long. Are we still confused?
    Presenters: Ken Wong, Deputy Director at Sanofi Pasteur and Diego Zurbriggen, Technical Account Manager at West Pharma

    Description:TBA
  • Introducing Chromassette®, a modular chromatography platform enabling next-gener
    Introducing Chromassette®, a modular chromatography platform enabling next-gener
    Ping Huang, Director, Head of DS BioProcesses, OED, Abbvie at Redwood and Masayoshi Nagaya, Sr. Global Technology Manager Apr 4 2019 5:00 pm UTC 75 mins
    Title: Introducing Chromassette®, a modular chromatography platform enabling next-generation bioprocess purification.

    We will introduce Chromassette® and an application example of an integrated rapid single pass process from harvest to purified bulk, a concept demonstrated by AbbVie. Chromassette is a stackable, single-use and pre-packed chromatography cassette with a supported bed, addressing the current key challenges in manufacturing. Chromassette enhances the separation capabilities of chromatography resins and combines it with the convenience of a modular cassette.